Cargando…
C-type natriuretic peptide analog treatment of craniosynostosis in a Crouzon syndrome mouse model
Activating mutations of fibroblast growth factor receptors (FGFRs) are a major cause of skeletal dysplasias, and thus they are potential targets for pharmaceutical intervention. BMN 111, a C-type natriuretic peptide analog, inhibits FGFR signaling at the level of the RAF1 kinase through natriuretic...
Autores principales: | Holmes, Greg, Zhang, Lening, Rivera, Joshua, Murphy, Ryan, Assouline, Claudia, Sullivan, Lorraine, Oppeneer, Todd, Jabs, Ethylin Wang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062116/ https://www.ncbi.nlm.nih.gov/pubmed/30048539 http://dx.doi.org/10.1371/journal.pone.0201492 |
Ejemplares similares
-
Integration of Brain and Skull in Prenatal Mouse Models of Apert and Crouzon Syndromes
por: Motch Perrine, Susan M., et al.
Publicado: (2017) -
Overexpression of Fgfr2c causes craniofacial bone hypoplasia and ameliorates craniosynostosis in the Crouzon mouse
por: Lee, Kevin K. L., et al.
Publicado: (2018) -
Mutations in the interleukin receptor IL11RA cause autosomal recessive Crouzon-like craniosynostosis
por: Keupp, Katharina, et al.
Publicado: (2013) -
Nonsyndromic Craniosynostosis: Novel Coding Variants
por: Sewda, Anshuman, et al.
Publicado: (2019) -
Titania nanotube-based protein delivery system to inhibit cranial bone regeneration in Crouzon model of craniosynostosis
por: Bariana, Manpreet, et al.
Publicado: (2019)